Mike King's questions to Salarius Pharmaceuticals (SLRX) leadership • Q3 2021
Question
Mike King of H.C. Wainwright & Co., LLC asked about the clinical strategy for seclidemstat in combination with pembrolizumab in gynecologic cancers, including the target patient population, line of treatment, and study design elements to ensure the benefit of seclidemstat is clear. He also asked if biomarker work would be included.
Answer
SVP of Clinical Development Nadeem Mirza stated the investigator-sponsored study will initially target relapsed/refractory patients to find the recommended Phase 2 dose. He described it as a proof-of-concept study that could open doors to other tumor types where checkpoint inhibitors are used. Mirza also confirmed that all Salarius studies have a biomarker component.